LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

80.55 1.97

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

79.88

Max

80.87

Galvenie mērījumi

By Trading Economics

Ienākumi

-252M

-129M

Pārdošana

-295M

157M

EPS

-0.613

Peļņas marža

-82.062

Darbinieki

1,069

EBITDA

-245M

-94M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+5.02% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.6B

13B

Iepriekšējā atvēršanas cena

78.58

Iepriekšējā slēgšanas cena

80.55

Ziņu noskaņojums

By Acuity

34%

66%

85 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 14. dec. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

2025. g. 13. dec. 00:04 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025. g. 14. dec. 23:46 UTC

Tirgus saruna

Gold Edges Higher Amid Some Tailwinds -- Market Talk

2025. g. 14. dec. 23:36 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025. g. 14. dec. 22:38 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Take Full Control of US$101M Copper Miner Alta

2025. g. 14. dec. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

2025. g. 14. dec. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Alta Owns the Canariaco Project in Northern Peru

2025. g. 14. dec. 22:01 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

2025. g. 14. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue: Agreement Implies Total Equity Value of C$139 Million

2025. g. 14. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

2025. g. 14. dec. 21:59 UTC

Iegādes, apvienošanās, pārņemšana

Fortescue to Acquire Remaining 64% of Alta Copper

2025. g. 14. dec. 17:00 UTC

Peļņas

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

2025. g. 14. dec. 08:30 UTC

Iegādes, apvienošanās, pārņemšana

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025. g. 13. dec. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025. g. 13. dec. 08:00 UTC

Iegādes, apvienošanās, pārņemšana

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025. g. 13. dec. 07:00 UTC

Iegādes, apvienošanās, pārņemšana

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

2025. g. 13. dec. 00:24 UTC

Iegādes, apvienošanās, pārņemšana

Want a Piece Of SpaceX? -- Barrons.com

2025. g. 12. dec. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025. g. 12. dec. 22:52 UTC

Tirgus saruna

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025. g. 12. dec. 22:32 UTC

Peļņas

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 20:45 UTC

Peļņas

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025. g. 12. dec. 20:41 UTC

Tirgus saruna

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025. g. 12. dec. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025. g. 12. dec. 19:23 UTC

Peļņas

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025. g. 12. dec. 18:35 UTC

Iegādes, apvienošanās, pārņemšana

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025. g. 12. dec. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025. g. 12. dec. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025. g. 12. dec. 17:49 UTC

Peļņas

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025. g. 12. dec. 17:34 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

5.02% augšup

Prognoze 12 mēnešiem

Vidējais 84.88 USD  5.02%

Augstākais 110 USD

Zemākais 65 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

15

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

Īstermiņā

Neutral Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

85 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat